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Abstract 
The prohormone thyroxine (T4) is activated by outer ring deiodination (ORD) to 3,3’,5_triiodothyronine (T3) and both hormones are degraded 
by inner ring deiodination (IRD) to 3,3’,5’-triiodothyronine (rT3) and 3,3’-diiodothyronine, respectively. Indirect evidence suggests that the type I 
iodothyronine deiodinase (ID-I) in liver has both ORD and IRD activities, with preference for rT3 and sulfated iodothyronines as substrates. To 
establish this, we have compared the ORD of rT3 and IRD of T3 and T3 sulfate by homogenates of cells transfected with rat ID-I cDNA and by 
rat liver microsomes. In both preparations rT3 is the preferred substrate, while deiodination of T3 is markedly accelerated by its sulfation. Kinetic 
analysis provided similar K,,, and V,,,,, values in cell homogenates and liver microsomes. These data demonstrate unequivocally that ID-I is capable 
of both activating and inactivating thyroid hormone by ORD and IRD, respectively. 
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1. Introduction 
In humans, as well as in rats, the major product se- 
creted by the thyroid follicular cells is the prohormone 
thyroxine (T4), which is activated in peripheral tissues by 
outer ring deiodination (ORD) to 3,3’,5_triiodothyronine 
(T3) or inactivated by inner ring deiodination (IRD) to 
3,3’,5’-triiodothyronine (rT3) [l-3]. T3 is also degraded 
by IRD to 3,3’-diiodothyronine (3,3’-T2), a metabolite 
which is also generated by ORD of rT3 [l-3]. The type 
II deiodinase in brain, pituitary and brown adipose tis- 
sue specifically catalyzes ORD of iodothyronines, while 
the type III deiodinase in brain, placenta, skin and sev- 
eral fetal tissues has only IRD activity [l-3]. However, 
circumstantial evidence suggests that the type I iodothy- 
ronine deiodinase (ID-I) is capable of both ORD and 
IRD [l]: (i) both activities have been localized in the 
microsomal fraction and show the same enrichment dur- 
ing > 103-fold enzyme purification [4,5]; (ii) they are af- 
fected in identical ways by a variety of substrate analogs 
and inhibitors [6,7]; (iii) they show identical kinetic 
*Corresponding author. Fax: (31) (10) 463 5430. 
mechanisms with dithiothreitol (DTT) as cofactor and 
propylthiouracil (PTU) as inhibitor [7]; and (iv) both 
activities are affected dramatically by sulfation of the 
substrate [8]. Thus, ID-I catalyzes the IRD of T4 sulfate 
and T3 sulfate (T3S) as well as the ORD of 3,3’-T2 
sulfate much better than the reactions with the non- 
sulfated substrates [S]. Although ID-I is thought to be 
very important for peripheral T3 production by ORD of 
T4, the enzyme is by far more effective in the ORD of 
the inactive metabolite rT3 [l-3]. 
Recently, the cDNAs of human and rat ID-I have 
been cloned and sequenced, showing that they represent 
homologous proteins with molecular weights of = 29 
kDa; both contain a selenocysteine (Set) residue as the 
catalytic center [9,10]. Deiodinase activity expressed by 
transfection of cell lines with the rat ID-I cDNA is very 
similar to ID-I activity in rat liver microsomes, including 
the substrate preference for rT3 over T4, the potent inhi- 
bition by PTU and gold compounds, and the ready label- 
ing of a = 29 kDa enzyme protein with N-bromoacetyl- 
[12’I]T3 [9-141. In this study we have analyzed the ORD 
of rT3 and IRD of T3 and T3S by homogenates of cells 
transfected with rat ID-I cDNA in comparison with rat 
liver microsomes. The results demonstrate that, indeed, 
ID-I is capable of both activation and inactivation of 
thyroid hormone. 
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2. Materials and methods 
2.1. Materials 
[3',5'-125I]rT3 (~ 1200#Ci/#g) was obtained from Amersham (Amer- 
sham, UK); [3,5-12SI]T3 (= 50 ,uCi/#g) and unlabeled T3, rT3 and T3S 
were supplied by MMDRI, Henning Berlin R&D (Berlin, Germany); 
[3,5-~25I]T3S was produced by sulfation of [3,5-~2SI]T3 as described 
before [15]; DTT was obtained from Sigma (St. Louis, MO, USA); and 
Sephadex LH-20 from Pharmacia (Woerden, The Netherlands). [t2SI]T3 
and [12Sl]T3S could be used without further purification, but [12SI]rT3 
was purified on Sephadex LH-20 before ach assay [16]. Male Sprague- 
Dawley rat liver microsomes were obtained as previously described [7]. 
2.2. Expression of rat ID-I 
Vectors pUHD10-3 (D10) and pUHD15-1 (D15) were obtained 
from Dr. Manfred Gossen [17,18]. The full length rat ID-I cDNA, G21 
[9], was cloned into D10 between the EcoRI and XbaI sites. The result- 
ing deiodinase expression vector, G21-D10, was cotransfected with the 
transactivation plasmid, D15, into human embryonic kidney (HEK) 
293 cells by CaPO4-DNA precipitation as described previously [9]. 
Controls were transfected with D10 vector plus D15 transactivator. 
Cultures were maintained in DMEM + 10% fetal calf serum in the 
absence of tetracycline. Cells were harvested 48 h after transfection, 
sonicated in 0.25 M sucrose, 100 mM sodium phosphate (pH 6.9), 
1 mM EDTA and 10 mM DTT, and snap-frozen i liquid nitrogen. 
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2.3. Deiodinase assays 
The principle of these assays was the production of radioiodide by 
ORD of [3',5'-125I]rT3 and IRD of [3,5-125I]T3 or [3,5-125I]T3S. Incuba- 
tion mixtures contained ~ 60,000 cpm labeled rT3 (= 0.2 nM), T3 
(~ 10 nM) or T3S (~ 10 nM), varying concentrations of unlabeled 
substrate, and varying amounts of cell homogenate or rat liver micro- 
somes in 200 #1 0.1 M phosphate (pH 7.2), 2 mM EDTA and 10 mM 
DTT. Mixtures were incubated in triplicate for 5-60 min at 37°C, and 
the reactions were stopped by the addition of 100 ,ul 5% bovine serum 
albumin at 0°C. Protein-bound iodothyronines were precipitated bythe 
addition of 500 #1 10% trichloroacetic a id, and the radioiodide in the 
supernatant was further isolated on mini Sephadex LH-20 columns as 
previously described [16]. Enzymatic deiodination was corrected for 
non-enzymatic 1251- production as determined in blank incubations 
without enzyme and multiplied by 2 to account for the random labeling 
and deiodination of the 3' and 5' positions in labeled rT3 or the 3 and 
5 positions in labeled T3 and T3S. 
In some experiments, IRD ofT3 was also determined byradioimmu- 
noassay (RIA). For this purpose, incubations were carried out as above 
using only unlabeled T3 as the substrate. These incubations were 
stopped by the addition of 800 #l 0.1 N NaOH, and 3,3'-T2 was 
measured directly in the resulting mixtures by specific RIA relative to 
standards prepared in the same vehicle as previously described [7]. 
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3. Results 
Homogenates of cells transfected with vector without 
insert were devoid of deiodinase activity towards the 
different substrates, but cells transfected with ID-I 
cDNA-containing vector (G21 cells) expressed eiodi- 
nase activities imilar to those in rat liver microsomes. 
Fig. 1 shows the IRD ofT3 and T3S as well as the ORD 
of rT3 at 1 #M substrate concentration by G21 cell ho- 
mogenates as a function of incubation time and cellular 
protein concentration. Significant deiodination was ob- 
served with all substrates tested, rT3 being deiodinated 
most rapidly, followed by T3S, while T3 was clearly the 
least active substrate. From the findings depicted in 
Fig. 1, proper conditions were chosen to analyze initial 
deiodination rates of the different substrates, and reac- 
Fig. 1. Deiodination of 1 #M T3, T3S or rT3 by G21 cell homogenate 
as a function of incubation time using 100 (T3), 50 (T3S) or 25 (rT3) 
#g cell protein/ml (A) or as a function of cell protein concentration 
during incubation for 30 min (B). Results are the means of triplicate 
incubations in a representative experiment. 
tion conditions were defined similarly for rat liver micro- 
somes (not shown). 
Table 1 gives the rates of the IRD of T3 and T3S and 
the ORD of rT3 by G21 cell homogenates a well as rat 
liver microsomes determined at 1 #M substrate concen- 
tration. Since the percentage deiodination of T3 was rel- 
atively small, IRD of this substrate was measured in 
these experiments by RIA of the product 3,3'-T2. Deiodi- 
nation rates were somewhat higher with G21 cell homo- 
genates than with rat liver microsomes, i.e. 2.2 and 2.3 
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times for IRD of T3 and T3S, respectively, and 1.3 times 
for ORD of rT3. 
Fig. 2 shows the Lineweaver-Burk plots for the IRD 
of T3S and the ORD of rT3 by G21 cell homogenates as 
well as rat liver microsomes, and Table 2 gives the appar- 
ent Km and I’,,, values derived from these plots. While 
I’,,, values for both T3S and rT3 were very similar with 
both enzyme preparations, mean apparent K,,, values 
were 2.7-fold lower for T3S and 1.4-fold lower for rT3 
when G2 1 cell homogenates were compared with rat liver 
microsomes. 
4. Discussion 
Since ID-I is thought to be very important for periph- 
eral production of T3 from T4 and since it shows optimal 
catalysis in the ORD of rT3 [l-3], the enzyme is usually 
referred to as an ORDase or 5’-deiodinase. However, 
much circumstantial evidence has been presented sug- 
gesting that ID-I has also IRDase or 5-deiodinase activ- 
ity [ 1,2], and this is proven unequivocally by the present 
results. Although IRD of T3 by ID-I is orders of magni- 
tude slower than the ORD of rT3, so is the rate by which 
T4 is converted to T3 by the same enzyme [l-3]. Since 
ID-I has both ORD and IRD activities, our present find- 
ings support the hypothesis that this enzyme is capable 
of the activation as well as the inactivation of thyroid 
hormone. 
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Besides deiodination thyroid hormone is also metabol- 
ized by conjugation of the 4’-OH group with glucuronic 
acid or sulfate [ 191. Whereas the glucuronides are rapidly 
excreted in the bile, only a small proportion of the sul- 
fates is normally excreted intact as they are rapidly 
deiodinated in the liver [8,19]. In particular, IRD of both 
T4 and T3 is strongly facilitated by the sulfation of these 
compounds, suggesting that sulfation is a rate-limiting 
step preceding the deiodinative clearance of thyroid 
hormone [8,19]. The present findings clearly confirm pre- 
vious suggestions that the efficient deiodination of iodo- 
thyronine sulfates is catalyzed by ID-I. Since rat and 
human ID-I are basic proteins [9,10], this may be due to 
beneficial ionic interaction of the negatively charged 4’- 
sulfate group of the substrate with protonated residues 
0 2 4 6 8 10 
l/uM rT3 
Fig. 2. Lineweaver-Burk plots of the IRD of T3S (A) or ORD of rT3 
(B) by G21 cell homogenates (G21) or rat liver microsomes (Mx). 
Results are the means of triplicate incubations in a representative exper- 
iment. 
Table 1 
Deiodinase activities of G21 cell homogenate and rat liver microsomes 
Reaction G21 cells Rat liver 
(pmol/min/mg protein) 
in the enzyme active center [20]. However, it remains to 
be established if this is indeed the mechanism for the 
facilitated deiodination of sulfated substrates by ID-I. 
T3 IRD 
T3S IRD 
rT3 ORD 
3.17 + 0.45 1.38 z!z 0.33 
246? 18 113 f 13 
461 f 51 348 f 35 
Results represent the means f S.E.M. of 3-5 experiments each per- 
formed in triplicate at 1 ,uM substrate concentration. IRD of T3 was 
determined by RIA of 3,3’-T2. 
Our observations raise questions about, among other 
things, how ID-I can deiodinate both the outer and inner 
ring of different iodothyronines, and if structural modifi- 
cations of the protein may differentially affect these two 
activities. It can be envisioned that the enzyme has a 
single, relatively wide binding pocket to which substrate 
can bind with a considerable degree of freedom, so that 
the iodine atoms of both rings may be in close proximity 
to the catalytic center, i.e. the Set residue [ 141. However, 
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Table 2 
Kinetics of T3S and rT3 deiodination by G21 cell homogenate and rat 
liver microsomes 
Reaction Enzyme K, 01M) V,,, (pmoYmin/mg) 
T3S IRD G21 cells 4.7 + 1.1 1,396 f 150 
Rat liver 12.5 f 3.8 1,377 f 197 
rT3 ORD G21 cells 0.49 + 0.10 646 f 112 
Rat liver 0.68 ? 0.19 552 f 3 
Results represent the means f S.E.M. of 2-3 experiments such as 
shown in Fig. 2. 
there may also be two distinct binding modalities, so that 
binding of substrate in one orientation would favour 
interaction of Set with the outer ring iodines, while in the 
alternative orientation the inner ring iodines would be 
preferentially exposed. There is no evidence that ID-I is 
composed of different subunits, although the enzyme 
may be a homodimer [3]. However, based on substrate 
competition experiments, it is unlikely that ID-I has sep- 
arate ORD and IRD substrate-binding sites [6,7]. 
Regulation of thyroid hormone bioactivity could in- 
volve changes in the relative ORD and IRD activities by 
post-translational modification of ID-I. Although a con- 
sensus glycosylation site has been identified in the amino 
acid sequences of human and rat ID-I, it is not known 
if the enzyme is indeed glycosylated in vivo [9, lo]. Recent 
studies with several ID-I mutants have demonstrated the 
essential nature of Set and two His residues for the ORD 
activity of the enzyme [9,1 l-l 31. Preliminary evidence 
suggests that modifications of these residues results in 
parallel decreases in IRD activity (M. Moreno, M.J. 
Berry, P.R. Larsen and T.J. Visser, unpublished observa- 
tions). It is of great interest to further investigate if mod- 
ifications of other residues may be associated with selec- 
tive changes in either ORD or IRD activity of the en- 
zyme. The enzyme expressed in HEK 293 cells shows 
somewhat lower K, values than native ID-I, more so for 
the IRD substrate, T3S, than for the ORD substrate, 
rT3. Although it is not excluded that this is due to a 
difference in post-translational modification, it may very 
well reflect differences in environment of the enzyme in 
the two preparations. 
In conclusion, our findings demonstrate that the type 
I deiodinase is capable of outer and inner ring deiodina- 
tion of iodothyronines, and, thus, can both activate and 
inactivate thyroid hormone. It is not known if the regu- 
lation of thyroid hormone bioactivity involves differen- 
tial alterations of these two activities. 
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